Ilaris (canakinumab) Please rate this page (bottom of page)

Share Button

Ilaris are injections (150 mg / ml syringe) containing canakinumab against Still's syndrome and more periodic fever syndromes / auto-inflammatory diseases. Ilaris can also be used against seizures gout

Ilaris is a biological treatment that works by inhibiting the immune system Intererleukin-1 (IL-1) and thus rheumatic inflammation in some diseases.

Before start of treatment

Ilaris should not be used in severe infection. Tuberkulosis (Tbc) and other chronic infections must be ruled out. "Live" vaccines (Rota virus, MMR, Yellow fever and more) should not be given during treatment while "Dead" vaccines (Influenza, Meningococci, Pneumococci) can usually be used.

Ilaris should not be combined with TNF inhibitors (other biological treatment) because the risk of infection increases. Live vaccines should not be given during treatment.

To assess efficacy (after, for example, 3 months of treatment), measurements of disease activity at baseline and during treatment are important. Before starting treatment, one should define a treatment goal.

Pregnancy and breast-feeding

There is still too little data to be sure that Ilaris cannot cause pregnancy. Therefore, Ilaris should only be used during pregnancy if needed, and there are no better alternatives.


The dosage for children follows body weight. For weights over 40 kg, 150 mg every 4-8 is recommended. week). If needed, the dose is increased after one week. In case of gout attacks, a single dose of 150 mg can be given. Ilaris should not be given to children under 2 years of age because efficacy and safety data are lacking.


Side effects

Side effects may occur and the risk must be compared with the indication for treatment. Common side effects:

  • Pain in the insertion site
  • Joint pain
  • Muscle pain
  • Increased risk of infections
  • Abdominal pain
  • Dizziness
  • Low white blood cell count (leukopenia) and neutropenia
  • Reduced renal function

Checks and follow-up

Medical examinations should rule out signs of side effects and then whether the effect is as desired. In case of recurrent infections, it may be necessary to stop the treatment. The specialist assesses whether the treatment goal has been reached and how long treatment is needed.

For more information is recommended

- Medications for rheumatic diseases

This page has had 1 visits today

Please rate this page